Skip Navigation
Skip to contents

JPTM : Journal of Pathology and Translational Medicine


Author index

Page Path
HOME > Articles and issues > Author index
Hyo Jung Kim 1 Article
Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas
Soo Kee Min, Young Ho Koh, Yunwoong Park, Hyo Jung Kim, Jinwon Seo, Hye-Rim Park, Seong Jin Cho, In Sun Kim
Korean J Pathol. 2012;46(2):142-150.   Published online April 25, 2012
  • 6,179 View
  • 60 Download
  • 19 Citations
AbstractAbstract PDF

It has generally been proven that histone acetylation and deacetylation are involved in the malignant transformation. To date, however, this has rarely been studied in cases of malignant lymphoma.


We studied nine cases of reactive lymphoid hyperplasia, 78 cases of diffuse large B-cell lymphoma (DLBCL), 13 cases of peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), and 13 cases of extranodal NK/T-cell lymphoma, nasal type (NKTCL). Thus, we attempted to elucidate the associations of the degree of the expression of histone acetyltransferase 1 (HAT1), histone deacetylase (HDAC) 1, HDAC2, and HDAC3 with the clinical behaviors of above malignant lymphomas using the immunohistochemistry and a western blot analysis.


The degree of the expression of HAT1 was higher in cases of DLBCL, PTCL-NOS or NKTCL as compared with reactive lymphoid hyperplasia (p<0.05). The degree of the expression of HAT1 was correlated with that of HDAC1 in cases of DLBCL or NKTCL (p<0.05). The degree of the expression of HAT1 and HDAC1 was correlated with a poor survival in cases of DLBCL or PTCL-NOS (p>0.05).


HAT1, HDAC1, and HDAC2 play a critical role in the development of malignant lymphomas. Both HAT1 and HDAC1 might be indicators for a poor prognosis in cases of DLBCL as cooperating factors.


Citations to this article as recorded by  
  • Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies
    Ailin Zhao, Hui Zhou, Jinrong Yang, Meng Li, Ting Niu
    Signal Transduction and Targeted Therapy.2023;[Epub]     CrossRef
  • Potential Therapeutic Use of Aptamers against HAT1 in Lung Cancer
    José Ignacio Klett-Mingo, Celia Pinto-Díez, Julio Cambronero-Plaza, Rebeca Carrión-Marchante, Miriam Barragán-Usero, María Isabel Pérez-Morgado, Eulalia Rodríguez-Martín, Mª Val Toledo-Lobo, Víctor M González, M. Elena Martín
    Cancers.2022; 15(1): 227.     CrossRef
  • Modulation of serine/threonine-protein phosphatase 1 (PP1) complexes: A promising approach in cancer treatment
    Bárbara Matos, John Howl, Carmen Jerónimo, Margarida Fardilha
    Drug Discovery Today.2021; 26(11): 2680.     CrossRef
  • Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer
    Yan Sun, Dianyun Ren, Yingke Zhou, Jian Shen, Heshui Wu, Xin Jin
    Cell Death & Disease.2021;[Epub]     CrossRef
  • Deciphering genes associated with diffuse large B-cell lymphoma with lymphomatous effusions: A mutational accumulation scoring approach
    Sina Abdollahi, Seyedeh Zahra Dehghanian, Liang-Yi Hung, Shiang-Jie Yang, Dao-Peng Chen, L. Jeffrey Medeiros, Jung-Hsien Chiang, Kung-Chao Chang
    Biomarker Research.2021;[Epub]     CrossRef
  • The contributory roles of histone deacetylases (HDACs) in hematopoiesis regulation and possibilities for pharmacologic interventions in hematologic malignancies
    Mahdieh Mehrpouri, Atieh Pourbagheri-Sigaroodi, Davood Bashash
    International Immunopharmacology.2021; 100: 108114.     CrossRef
  • Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma
    Mingyang Wang, Xiaosheng Fang, Xin Wang
    Leukemia & Lymphoma.2020; 61(4): 763.     CrossRef
  • Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases

    Lijun Du, Lei Zhang, Ling Li, Xin Li, Jiaqin Yan, Xinhua Wang, Xiaorui Fu, Zhenchang Sun, Xudong Zhang, Zhaoming Li, Jingjing Wu, Hui Yu, Yu Chang, Zhiyuan Zhou, Feifei Nan, Xiaolong Wu, Li Tian, Mingzhi Zhang
    OncoTargets and Therapy.2020; Volume 13: 7189.     CrossRef
  • Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer
    Ping Fan, Jingyuan Zhao, Zibo Meng, Heyu Wu, Bo Wang, Heshui Wu, Xin Jin
    Journal of Experimental & Clinical Cancer Research.2019;[Epub]     CrossRef
  • Histone modifications: A review about the presence of this epigenetic phenomenon in carcinogenesis
    Emanuely Silva Chrun, Filipe Modolo, Filipe Ivan Daniel
    Pathology - Research and Practice.2017; 213(11): 1329.     CrossRef
  • Histone Acetyltransferase 1 Promotes Cell Proliferation and Induces Cisplatin Resistance in Hepatocellular Carcinoma
    Xin Jin, Shenghua Tian, Pingping Li
    Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics.2017; 25(6): 939.     CrossRef
  • HDACs and HDAC Inhibitors in Cancer Development and Therapy
    Yixuan Li, Edward Seto
    Cold Spring Harbor Perspectives in Medicine.2016; 6(10): a026831.     CrossRef
  • Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies
    Diana Markozashvili, Vincent Ribrag, Yegor S. Vassetzky
    Investigational New Drugs.2015; 33(6): 1280.     CrossRef
  • Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
    Hervé Ghesquieres, Susan L. Slager, Fabrice Jardin, Amelie S. Veron, Yan W. Asmann, Matthew J. Maurer, Thierry Fest, Thomas M. Habermann, Marie C. Bene, Anne J. Novak, Sylvain Mareschal, Corinne Haioun, Thierry Lamy, Stephen M. Ansell, Herve Tilly, Thomas
    Journal of Clinical Oncology.2015; 33(33): 3930.     CrossRef
  • Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis
    Tobias Wagner, Peter Brand, Thorsten Heinzel, Oliver H. Krämer
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2014; 1846(2): 524.     CrossRef
  • Targetome profiling and functional genetics implicate miR-618 in lymphomagenesis
    Alan Fu, Aaron E Hoffman, Ran Liu, Daniel I Jacobs, Tongzhang Zheng, Yong Zhu
    Epigenetics.2014; 9(5): 730.     CrossRef
  • Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
    Jinwon Seo, Soo Kee Min, Hye-Rim Park, Dong Hoon Kim, Mi Jung Kwon, Lee Su Kim, Young-Su Ju
    Journal of Breast Cancer.2014; 17(4): 323.     CrossRef
  • Diffuse large B-cell lymphoma
    Maurizio Martelli, Andrés J.M. Ferreri, Claudio Agostinelli, Alice Di Rocco, Michael Pfreundschuh, Stefano A. Pileri
    Critical Reviews in Oncology/Hematology.2013; 87(2): 146.     CrossRef
  • Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma
    Kelly A. Cycon, Kathleen Mulvaney, Lisa M. Rimsza, Daniel Persky, Shawn P. Murphy
    Immunology.2013; 140(2): 259.     CrossRef

JPTM : Journal of Pathology and Translational Medicine